Intro; Preface; Contents; Contributors; Part I: Diabetes, Insulin Resistance, and the Metabolic Syndrome; 1: Insulin Resistance and the Metabolic Syndrome in Kidney Disease (e.g., the Cardiorenal Metabolic Syndrome); Introduction; Definition(s) of the Cardiorenal Metabolic Syndrome; Epidemiology of the Cardiorenal Metabolic Syndrome; The Cardiorenal Metabolic Syndrome and CKD; Insulin Resistance/Hyperinsulinemia; Inflammatory Cytokines; Inappropriate Activation of the RAAS; Endothelial Dysfunction; Conclusions and Perspectives; References; 2: Diabetic Kidney Disease; Epidemiology

PathophysiologyNatural History; Diagnosis; Prevention and Treatment; Complications of Chronic Kidney Disease; Conclusions; References; 3: Glucose Homeostasis and the Burnt-Out Diabetes Phenomenon in Patients with Kidney Disease; Introduction; Glucose Homeostasis in Kidney Disease; Clearance of Insulin; Hypoglycemia Due to Antidiabetic and Other Agents; Decreased Gluconeogenesis in the Kidney; Insulin Secretion and Insulin Resistance; Protein-Energy Wasting (PEW); Burnt-Out Diabetes Phenomenon; Hemodialysis-Related Hypoglycemia and Hyperglycemia; Hemodialysis-Induced Hypoglycemia

Metabolic Effects Associated with Glucose-Free DialysateHemodialysis-Associated Hyperglycemia; Insulin Removal by Hemodialysis; Hemodialysis-Associated Hyperglycemia Resembling the Somogyi Effect; References; 4: Glycemic Metrics and Targets in Kidney Disease; Introduction; Glycemic Metrics and Their Role in Kidney Disease; Glycated Hemoglobin (A1C); Glycated Albumin (GA); Fructosamine; 1,5-Anhydroglucitol (1,5-AG); Continuous Glucose Monitoring (CGM); Glycemic Targets in Kidney Disease; Conclusion; References; 5: Diabetic Pharmacotherapies in Kidney Disease; Introduction; Biguanides

SulfonylureasMeglitinides; Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs); Dipeptidyl Peptidase IV (DPP-4) Inhibitors; Thiazolidinediones; Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors; Alpha-Glucosidase Inhibitors; Bromocriptine; Bile Acid Resins; Insulin; Amylin Analog; Impact of Antihyperglycemic Agents on Renal Function; Conclusion; References; 6: Diabetes Mellitus and Renal Transplantation; Introduction; Changes in Glucose Homeostasis During Peri-Kidney Transplantation; Changes in Glucose Homeostasis During the Immediate Posttransplant Period

New-Onset Diabetes After Kidney TransplantationClinical and Economic Significance of NODAT; It Is Important to Decrease the Incidence of NODAT; Timing of NODAT; Pathogenesis of NODAT; Can Lifestyle Modification Be Adapted for Prevention of NODAT?; Drugs for Preventing NODAT; Conclusion; References; Part II: Thyroid Dysfunction; 7: Evaluating Thyroid Function Tests in Patients with Kidney Disease; Introduction; TSH Measurement; TSH Levels in Chronic Kidney Disease Patients; Measuring Free Thyroxine and Free Triiodothyronine; Thyroxine (T4) Changes with CKD; Triiodothyronine and Reverse Triiodothyronine in CKD